A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy
SGT-003-101
Phase 2 other active
Quick answer
A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy for Duchenne muscular dystrophy is a Phase 2 program (other) at Solid Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Solid Biosciences
- Indication
- Duchenne muscular dystrophy
- Phase
- Phase 2
- Modality
- other
- Status
- active